COVID-19 caused shockwaves throughout the global supply chain of every industry. For the pharmaceutical industry, the pandemic highlighted the fragility of the supply chain and the importance of being able to adjust to demand in a changed environment.

“A fully integrated clinical trial ancillary supply chain (CTASC) relies on strategic partners, infrastructure, and information technologies that simplify communication and streamline exchanges of information among multiple parties.” said Dr. Joanne Santomauro, Ancillare CEO and Founder.

As published in PharmaVOICE